Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
about
Serum C-Reactive Protein and Congestive Heart Failure as Significant Predictors of Herpes Zoster Vaccine Response in Elderly Nursing Home Residents.Shingles (Herpes Zoster) Vaccine (Zostavax(®)): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia.Varicella-Zoster Virus Glycoproteins: Entry, Replication, and Pathogenesis.Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine.Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.Vaccines for the elderly: current use and future challenges.Herpes Zoster in the Older Adult.Varicella and herpes zoster vaccine development: lessons learned.Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults.[Attenuated zoster vaccine is not recommended as a standard vaccine : Missed opportunity or logical implementation of the evidence-based approach of the Standing Committee on Vaccination].[Protection from a dormant time bomb: The development of effective vaccines against herpes zoster].Herpes Zoster Vaccine: Time for a Boost?Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged ≥50 Years.Reduced NK cell IFN-γ secretion and psychological stress are independently associated with herpes zoster.Breadth and functionality of varicella zoster virus glycoprotein-specific antibodies identified after Zostavax vaccination in humans.A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profileEfficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis
P2860
Q38609819-6209DDBE-9520-4231-BF6B-714A1A476B2AQ38836789-75A292CD-50BC-4FA1-8700-86C4D01E5E58Q39214502-F83730A5-F6B0-4B9C-96B9-4BEC43DBB2E0Q40162587-3DCD6437-E8AF-45E2-A968-680231293B58Q46046365-DD68FBA4-E11C-4406-8532-A8D56068AE02Q46892547-66824649-F585-4B52-98B1-1518142141ABQ47547388-9B70435A-D5F0-4F0F-B3E4-3B05117080DDQ47597541-9AE213D5-DEEE-4094-931B-BD57F69ECE71Q47607699-498FAA0B-DAA0-41A5-99D8-C9DD2C1F36E2Q49413352-5E90602C-21E5-476F-8AF2-2E9C0240C079Q50110542-B5824135-07CF-4062-AE9E-8AE98D45EDB8Q50619438-3DE3AE84-983B-4306-A6D6-804631BD62C9Q51774491-336E5AF9-A1C4-4E6C-BBEF-58D117679C97Q52727148-472751DC-575E-46BA-80AB-255E08F823F1Q52731228-60A97EFE-ED3A-4F1D-B162-7FD6BCDAB638Q54216748-2B36DA6E-95D3-4B68-9638-ADB520F13DDAQ56888201-2EE4FCD9-BC42-4508-A3B3-425E44D0FF75Q58553251-3FCD6A9B-E7A2-4A27-A949-90A01CE30BC4
P2860
Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Cellular and Humoral Responses ...... First Dose Among Older Adults.
@en
type
label
Cellular and Humoral Responses ...... First Dose Among Older Adults.
@en
prefLabel
Cellular and Humoral Responses ...... First Dose Among Older Adults.
@en
P2093
P2860
P356
P1476
Cellular and Humoral Responses ...... First Dose Among Older Adults.
@en
P2093
Adriana Weinberg
Angela Williams-Diaz
Gary Zerbe
Janie Parrino
Jennifer Canniff
Kenneth E Schmader
Michael J Johnson
Myron J Levin
P2860
P356
10.1093/INFDIS/JIV480
P407
P577
2015-10-09T00:00:00Z